- Improved early detection and diagnostics for breast cancer
- Sole commercial partner in the EU project
- MeVis Group to receive funding of around one million euros
Bremen, July 8, 2008. MeVis Medical Solutions AG [ISIN: DE000A0LBFE4] has been awarded a role in an innovative breast cancer research project by the European Union: On behalf of the European Institute for Biomedical Imaging Research (EIBIR), the Bremen-based specialist in disease-oriented software solutions in image-based medical technology will be working on further improvements to the early detection of and diagnostics for breast cancer.
MeVis Medical Solutions is the only commercial partner in this newly established syndicate, which comprises a further seven leading international university and clinic facilities in Europe alongside the non-profit research institute MeVis Research. All told, the MeVis Group will be receiving funding of around one million euros towards its involvement in the “HAMAM” project, which will have a duration of 36 months. “We are pleased to have been able to convince EIBIR of the merits of this research project,” says Dr. Carl J.G. Evertsz, CEO of MeVis Medical Solutions. “Via this project, we will be able to show once more - this time at a European level - what top innovative performance in the breast care segment means and demonstrate our innovativeness and technological leadership in image-based medical technology.” The Bremen-based company has previously successfully completed the EU SCREEN and SCREEN-TRIAL breast cancer projects.
The new project aims to consolidate all imaging processes in a single workstation. This makes it possible to overcome the barriers resulting from the hitherto isolated use of the imaging processes available. At the same time, a comprehensive database will be established to supply medical practitioners with additional information for diagnostic purposes. The system uses certain algorithms to evaluate the information gained on the patient during medical examinations and recommends further imaging processes on this basis. This multimodal workstation can be subsequently utilized on a cross-vendor basis, meaning that all available equipment can be connected.
“Uniting the various imaging processes in a single system is a revolutionary step, which not only facilitates medical practitioners’ work but also makes a decisive contribution to successful breast cancer early detection and diagnostics,” explains Evertsz. “The automatic process management system is a true innovation as it offers medical practitioners recommendations for further appropriate procedures. MeVis Medical Solutions will be contributing its proprietary software development platform “MeVisAP” for the duration of the research project as a basis for developing the work station and the software solutions for the various imaging processes.
The most modern forms of early detection and diagnostics are available for breast cancer. New kinds of imaging processes, such as 3D ultrasonics and tomosynthesis, supplement the established methods. Explains Evertsz: “What is decisive is for all available applications to be used efficiently for the benefit of the patients and to ready these farreaching improvements to early detection and diagnostics for the market as quickly as possible.”